|
Passage Bio, Inc. (PASG) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Passage Bio, Inc. (PASG) Bundle
Simplifiez Passage Bio, Inc. (PASG) Valation avec cette calculatrice DCF personnalisable! Doté de Real Passage Bio, Inc. (PASG) Financials and Rajustement des entrées de prévision, vous pouvez tester les scénarios et découvrir la juste valeur de Passage Bio, Inc. (PASG) en minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -36.6 | -112.9 | -185.7 | -138.4 | -98.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | .8 | 1.5 | 3.7 | 3.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -36.7 | -113.7 | -187.3 | -142.1 | -102.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 158.9 | 304.8 | 315.8 | 189.6 | 114.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .6 | 5.3 | 9.4 | 4.1 | 1.3 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.7 | -1.6 | -25.6 | -5.3 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -43.9 | -113.2 | -193.4 | -142.8 | -102.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -44.8 | -109.4 | -213.4 | -149.8 | -101.3 | -1.3 | .0 | .0 | .0 | .0 |
| WACC, % | 7.8 | 7.79 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | -6 | |||||||||
| Diluted Shares Outstanding, MM | 55 | |||||||||
| Equity Value Per Share | -0.11 |
What You Will Get
- Real PASG Financials: Access to historical and forecasted data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Passage Bio’s future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life PASG Financials: Pre-filled historical and projected data for Passage Bio, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Passage Bio’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Passage Bio’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the ready-to-use Excel file featuring Passage Bio, Inc.'s (PASG) financial data.
- Customize: Modify forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop multiple projections and compare results instantly.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Passage Bio, Inc. (PASG)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for biotechnology firms.
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios for Passage Bio.
- Detailed Insights: Automatically computes Passage Bio’s intrinsic value and Net Present Value.
- Preloaded Data: Access historical and projected data for accurate financial assessments.
- Professional Quality: Perfect for financial analysts, investors, and consultants focusing on the biotech sector.
Who Should Use Passage Bio, Inc. (PASG)?
- Investors: Gain insights into innovative therapies and make informed investment choices.
- Biotech Analysts: Utilize detailed reports and data to streamline your analysis process.
- Healthcare Consultants: Efficiently customize presentations or reports for clients in the biotech sector.
- Life Sciences Enthusiasts: Enhance your knowledge of gene therapies and their market implications.
- Educators and Students: Leverage real-world case studies to enrich learning in biotechnology and finance courses.
What the Template Contains
- Pre-Filled DCF Model: Passage Bio, Inc.’s (PASG) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Passage Bio, Inc.’s (PASG) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.